2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
3M agreed on November 3, 2026 to a settlement intended to resolve most PFAS-related personal injury claims in the AFFF multidistrict litigation. The company will contribute a nominal $7.35 billion from 2026 through 2034, with a present value of $5.8 billion, and will record that amount as a pre-tax charge in the fourth quarter of 2026. The company says the charge does not change its previously issued 2026 guidance, and payments depend on claimant participation thresholds.
Nominal commitment of $7.35 billion over 2026 to 2034; present value of $5.8 billion
Pre-tax charge of $5.8 billion in Q4 2026, treated as a special item in adjusted results; 3M says 2026 guidance is unchanged
$50 million payment due in 2026 and no payments in 2027; payments subject to claimant participation thresholds
Settlement covers about 99% of current personal injury claims, involving roughly 115,000 to 120,000 eligible plaintiffs; 3M does not admit liability
SeaStar Medical announced that the FDA's Center for Biologics Evaluation and Research determined the QUELIMMUNE Pediatric SAVE Surveillance Registry has fulfilled the post-approval study requirements of the original Humanitarian Device Exemption approval. The company says the decision lets hospitals use QUELIMMUNE without the research infrastructure the registry required, which could expand access for critically ill children with sepsis-associated acute kidney injury. The filing gives no revenue, earnings, or financial figures.
FDA's CBER determined the SAVE Registry met post-approval study requirements, announced November 3, 2026
Registry results showed 90-day survival of 65.1% for QUELIMMUNE patients (N=43) versus 47.5% for comparison patients (N=196), P = 0.043
SeaStar says hospitals may now use QUELIMMUNE without registry research infrastructure; the company will continue voluntary enrollment
Driven Brands said its Audit Committee found material fixed asset accounting errors in prior financial statements, including fiscal 2023 through 2025 and the first two 2026 quarterly reports, which must be restated and should not be relied upon. The company delayed its third quarter earnings call and will miss the November 5, 2026 deadline for its third quarter Form 10-Q, and it lowered its 2026 Adjusted EBITDA and Adjusted Diluted EPS outlook.
Audit Committee concluded prior financial statements for fiscal years 2023 to 2025 and the 2026 quarterly reports should not be relied upon; errors primarily involve fixed assets.
Third quarter 2026 Form 10-Q will not be filed by the November 5, 2026 due date; share repurchases are temporarily halted until the company is current on reporting.
2026 Adjusted EBITDA outlook cut to $410 million to $430 million from $430 million to $460 million; Adjusted Diluted EPS cut to $1.10 to $1.20 from $1.15 to $1.25.
Restatement-related costs expected to be at least $50 million in 2026; preliminary third quarter same store sales rose 2.0% for Driven Brands and 4.9% for Take 5.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.